1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Mental health and behavioural conditions
  5. Attention deficit disorder

Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents

Technology appraisal guidance [TA98] Published date: 22 March 2006

  • Guidance
  • Tools and resources
  • Information for the public
  • History
  • Share
    • Share
    • Linked In
    • Twitter
    • Facebook
    • Email
    • More...

Information for the public


  • Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents 22 March 2006   PDF 77.29 KB
NICE
  • About NICE
  • Into practice
  • News
  • Contact us
  • Leave feedback
  • Jobs
  • Newsletters and alerts
  • Blog
  • Twitter
  • YouTube
  •   Facebook
  • LinkedIn

Explore

  • Guidance
  • Pathways
  • Standards and indicators
  • Savings and productivity
  • Evidence search
  • BNF
  • BNFC
  • Clinical knowledge summaries
  • Journals and databases

Reusing our content

  • Reuse information
  • NICE UK Open Content Licence

Guidance app

  • Android
  • iOS

Get involved

  • Register as a stakeholder
  • Citizens council
  • Consultations
  • Fellows and scholars
  • Join a committee
  • Meetings in public
  • Student champions
  • Tenders
  • Public involvement
  • Accessibility
  • Freedom of information
  • Syndication services
  • Glossary
  • Terms and conditions

Copyright © 2017 National Institute for Health and Care Excellence. All rights reserved.